QMSMEDICALALLIED Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹172.9 Cr
verification pending
Revenue YoY
11%
reported change
EBITDA
₹25.9 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
QMS Medical Allied Services delivered 11% revenue growth to 172.9 crore in FY26, with EBITDA at 25.9 crore and PAT at 11.9 crore. While the top line growth was solid, EBITDA margins compressed to ~15% versus management's guided 17%, due to frontloaded investments in the services segment—specifically hiring ~1,200 employees for new patient service program contracts. The product segment faced supply chain disruptions in H2, causing revenue moderation. Management targets doubling service revenue to ~100 crore in FY27, driven by new GLP-1 related patient support programs and camp expansion. Camp revenue is guided at 18-20 crore. However, sustainability of the margin recovery remains uncertain as the company continues building infrastructure for new contracts. The main risk is margin pressure from pre-revenue investments and product segment supply headwinds, partially offset by strong visibility from locked-in service contracts.
Colored figures show movement against the previous available record.
Guidance to track
- Management confirmed being in line with the previously given revenue guidance of approximately 256 crore for FY27, representing ~48% growth over FY26's 172.9 crore.
- Management targets doubling service segment revenue from ~50 crore in FY26 to 100 crore in FY27, driven by new patient service program contracts and GLP-1 therapy launches by pharma clients.
- Revenue from healthcare camps expected to grow from ~13 crore in FY26 to 18-20 crore in FY27, with mixed camp pricing models based on type and patient volume.
- Management maintains confidence in achieving 18-19% EBITDA margins going forward, with service segment margins at 25% and product segment margins at 10-12%, as investments in new programs become productive.
Risks flagged
- Shipping disruptions and delays in supply of materials caused revenue moderation in H2 FY26. Management sees improvement in Q1-Q2 FY27 but the risk of recurring supply chain issues remains.
- Employee costs increased sharply from ~9.6 crore to 15.2 crore due to hiring 1,200 employees for new patient service programs. These are back-to-back contracted hires, but timing of revenue recognition creates near-term margin pressure.
- Analyst raised concerns about online-only pharma distribution players with deep pockets disrupting the market. Management deflected by emphasizing patient management focus but did not provide concrete competitive differentiation strategies.
- Management stated camp revenue at ~13 crore for FY26, while the presentation showed 16 crore for 9 months. Management asked to send revised details, suggesting potential data inconsistency that warrants verification.
Key quotes
- The epicenter of all these things is the patient actually. Managing the patient is becoming our most important thing right now in this entire order.
- These are new hires. All the new hirings is on our service segment. For one of the programs that we've signed up, our target is to hire 1,200 employees. So we can't have 1,200 employees coming in just in a month.
- Traditional Indian pharma companies who earlier would have never thought or were very averse to these support programs are now opening up and coming to QMS because we have the experience and track record to show that we can efficiently handle all of these patients.
Research modules